After taking a GLP-1 drug for just a few months, some people find themselves legally blind, with grave gastrointestinal issues, and other serious side effects. They were not ever told about these risks, reports Ariana Eunjung Cha and Daniel Wu for the Washington Post. And their manufacturers dispute that GLP-1s are the cause of these conditions.
To be sure, GLP-1s appear to be working safely and effectively for millions of Americans, improving their health. People who take GLP-1 drugs lose weight. And, Medicare now covers these drugs for people needing help losing weight, even if they do not have another condition.
GLP-1 drugs can treat diabetes and heart disease. But, given potential serious risks from taking GLP-1 drugs, shouldn’t Wegovy, Zepbound, Ozempic and the other GLP1s have a warning label indicating the possibility of serious harm?
The drugs all have warning labels, but the warnings focus on relatively minor and short-lived potential side effects such as nausea, constipation, indigestion and diarrhea. The warning labels do not include these far more serious possible side effects:
Osteoporosis and fragility fractures — One early study sees a link between GLP-1 use and osteoporosis. Older adults with diabetes on GLP-1 drugs face a greater risk of fragility fractures.
Nutritional deficiencies — Several studies have found that some people who take GLP-1s lack vitamin D, iron and calcium, or have other nutritional deficiencies. These nutritional deficiencies affect people’s fat, as well as their muscle mass and bone.
Cancer–Thyroid C-cell tumors are a possible risk. Studies found them in rats and mice on GLP-1s. Studies have not linked GLp-1s to thyroid, pancreatic, breast or kidney cancer. It’s possible that being on GLP-1s leads to less risk of obesity-related and other cancers.
Vision issues–The evidence does not suggest there is a serious risk of vision impairment or other eye issues from taking GLP-1 drugs. Indeed one study found lower rates of macular degeneration for people taking GLP-1s. But, another study shows some evidence of a risk of “eye stroke” or NAION, nonarteritic anterior ischemic optic neuropathy. GLP-1s could be linked to disruption of blood flow to the optic nerve which causes blindness. As a result, the FDA just required GLP-1 makers to include a warning of a potentially higher risk of NAION.
Digestive tract problems: In some cases, people who take GLP-1 drugs suffer from gastroparesis; their stomach empties too slowly. Again, cause and effect have not been proved.
Gallbladder and pancreatic problems — People on GLP-1s risk getting gallstones. One study found a 46 percent increase of this risk.
Menstrual changes — Some women see changes to their menstrual cycle and unusual bleeding. One recent study found that after taking a GLP-1 semaglutide for six months, women who had not been ovulating, began ovulating.
Hair loss: One study found that people with Type 2 diabetes who took GLP-1 drugs had an increased risk of hair loss.
Here’s more from Just Care:
- Some overweight individuals are ineligible for Medicare GLP-1 pilot with $50 copays
- The possible anti-cancer benefits of Ozempic and other GLP-1 drugs
- Beginning July 2026, Medicare will cover GLP-1s for people who want to lose weight
- Whether you’re taking a weight-loss drug or not, you’re paying for it
- Good news for anyone looking for help losing weight



